中国上海学龄前儿童百日咳加强免疫接种的成本效果分析
该研究采用马尔可夫决策树模型,从社会视角评估上海6岁学龄前儿童两种百日咳免疫策略:接种1剂含无细胞百日咳成分疫苗(DTaP或Tdap)加强针与不接种加强针,研究周期14年。结果显示,与不接种加强针相比,接种加强针人均成本降低814.16元人民币(116美元),QALYs增加0.00066,人均净货币效益增加933.51元人民币(132美元)。结论认为对上海6岁学龄前儿童实施无细胞百日咳加强免疫是节约成本的免疫策略。
要点
- 与不接种加强针相比,6岁接种1剂含aP疫苗加强针人均成本降低814.16元人民币(116美元)。
- 加强免疫策略人均QALYs增加0.00066,人均净货币效益增加933.51元人民币(132美元)。
核心结论
- 对上海6岁学龄前儿童实施含无细胞百日咳成分疫苗加强免疫是节约成本的免疫策略,同时带来成本节约和效用增益。
研究设计与样本
- 采用马尔可夫决策树模型,从社会视角评估上海6岁学龄前儿童两种百日咳免疫策略,研究周期14年。
- 策略1为6岁时接种1剂含无细胞百日咳成分疫苗(DTaP或Tdap)加强针;策略2为6岁时不接种加强针。
- 主要结局包括质量调整生命年(QALYs)、成本和增量成本效用比(ICUR),并进行了敏感性分析。
主要发现
- 与不接种加强针策略相比,6岁接种1剂含aP疫苗加强针人均成本降低814.16元人民币(116美元),QALYs增加0.00066,人均净货币效益增加933.51元人民币(132美元)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, notified pertussis cases have been increasingly documented in China. It raised a new public health concern of potential optimization in immunization strategy. This study was aimed to determine the cost-effectiveness of different immunization strategies against pertussis-containing vaccines for 6-year-old pre-school children in Shanghai. METHODS: A Markov-decision tree model was applied to evaluate two pertussis immunization strategies for 6-year-old pre-school children as following: (1) 1 dose of acellular pertussis (aP) contained vaccine (DTaP or Tdap) booster vaccinated at 6 years of age, and (2) no booster at 6 years of age regimen. Primary outcomes included quality-adjusted life years (QALYs), costs, and incremental cost-utility ratios (ICUR). Sensitivity analyses were performed. The analysis was conducted over a study period of 14 years from a societal perspective. RESULTS: Compared to no booster immunization strategy, administering 1 dose of acellular pertussis (aP) contained vaccine (DTaP or Tdap) booster at 6 years of age, resulted in an average cost reduction of CNY 814.16 (USD 116) per individual, an increase in QALYs by 0.00066, and a rise in per capita net monetary benefit (NMB) by CNY 933.51 (USD 132). The total costs over the study period were reduced by CNY 160.59 million (USD 23 million), utility increased by 130.49 QALYs, and NMB increased by CNY 184.14 million (USD 26 million). CONCLUSIONS: Implementing acellular pertussis booster immunization for 6-year-old pre-school children in Shanghai emerges as a cost-saving immunization strategy, with both cost savings and utility gains.
引用
- Ren J, Huang Z, Tian J, et al. Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis. Vaccine. 2024. PMID: 39069462. doi:10.1016/j.vaccine.2024.126162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。